您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > ORY-1001(trans)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ORY-1001(trans)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ORY-1001(trans)图片
CAS NO:1431303-72-8
包装与价格:
包装价格(元)
10mM (in 1mL Water)电议
5mg电议
50mg电议
100mg电议

产品介绍
Iadademstat (ORY-1001) dihydrochloride 是一种选择性不可逆赖氨酸 (K) 特异性去甲基化酶 1A (KDM1A/LSD1) 抑制剂。
Cas No.1431303-72-8
别名ORY-1001 dihydrochloride; RG6016 dihydrochloride; RO 7051790 dihydrochloride
Canonical SMILESN[C@@H]1CC[C@@H](N[C@H]2[C@H](C3=CC=CC=C3)C2)CC1.[H]Cl.[H]Cl
分子式C15H24Cl2N2
分子量303.27
溶解度Water: 57.75 mg/mL (190.42 mM and warming); DMSO: 0.69 mg/mL (2.28 mM and warming)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor. KDM1A/LSD1[1]

ORY-1001 trans is a KDM1A inhibitor that inactivate KDM1A by irreversible binding to the flavin adenine nucleotide (FAD) cofactor. ORY-1001 trans has very high selectivity for KDM1A over the MAO enzymes, high selectivity over KDM1B and unrivaled subnanomolar cellular activity in differentiation and colony formation assays on mixed lineage leukemia (MLL)-translocated acute myeloid leukemia (AML) cell lines. ORY-1001 provokes a time and dose-dependent induction of the Cd11b differentiation marker in MLL-AF9 cells, which interestingly preceeds changes in H3K4me2 levels. While MLL-translocated cells are especially sensitive, other acute leukemia (AL) cell lines also respond to ORY-1001 trans[1].

ORY-1001 trans reduces AML tumor growth in mice and rat xenografts and increases survival time in a disseminated model of T-ALL[1].

[1]. Maes T, et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics. 2015;7(4):609-26. doi: 10.2217/epi.15.9.